{"id":7865,"date":"2021-06-23T16:23:51","date_gmt":"2021-06-23T14:23:51","guid":{"rendered":"https:\/\/www.anderapartners.com\/?p=7865"},"modified":"2021-06-23T16:23:51","modified_gmt":"2021-06-23T14:23:51","slug":"poxel-annonce-lapprobation-de-twymeeg-pour-le-traitement-du-diabete-de-type-2","status":"publish","type":"post","link":"https:\/\/www.anderapartners.com\/fr\/poxel-annonce-lapprobation-de-twymeeg-pour-le-traitement-du-diabete-de-type-2\/","title":{"rendered":"Poxel annonce l\u2019approbation de TWYMEEG\u00ae pour le traitement du diab\u00e8te de type 2"},"content":{"rendered":"

TWYMEEG\u00ae est un m\u00e9dicament premier de sa classe dot\u00e9 d’un double m\u00e9canisme d’action unique pour le traitement du diab\u00e8te de type 2 qui s\u2019inscrit dans le paradigme actuel de traitement, en monoth\u00e9rapie ou en compl\u00e9ment d’autres traitements antidiab\u00e9tiques.<\/p>\n

L’autorisation au Japon d\u00e9clenche un paiement d’\u00e9tape de 1,75 milliard de yens japonais (environ 13,3 millions d\u2019euros, 15,9 millions de dollars) de la part de Sumitomo Dainippon Pharma.<\/p>\n

Le lancement commercial du TWYMEEG est pr\u00e9vu au cours de l\u2019ann\u00e9e fiscale 2021.<\/p>\n

L’approbation du TWYMEEG au Japon repose sur les r\u00e9sultats positifs du programme TIMES de phase III chez plus de 1 100 patients au Japon.<\/p>\n

Poxel est accompagn\u00e9 depuis plusieurs ann\u00e9es par Andera Life Sciences, l\u2019\u00e9quipe d\u2019Andera Parners d\u00e9di\u00e9e \u00e0 l\u2019innovation th\u00e9rapeutique. Pour Rapha\u00ebl Wisniewski, associ\u00e9 au sein de l\u2019\u00e9quipe Life Sciences : \u00ab l\u2019approbation d\u2019un produit est un r\u00e9el accomplissement dans la vie des soci\u00e9t\u00e9s que nous accompagnons. Nous sommes convaincus du potentiel du TWYMEED et de l\u2019int\u00e9r\u00eat qu\u2019il repr\u00e9sente pour les patients atteint de diab\u00e8te de type II \u00bb<\/em> .<\/p>\n

L\u2019approbation de TWYMEEG\u00ae constitue la deuxi\u00e8me approbation d\u2019un m\u00e9dicament depuis le d\u00e9but de l\u2019ann\u00e9e 2021 pour le portefeuille d\u2019Andera Life Sciences. En mars dernier, \u00a0Ontozri\u00ae (cenobamate), d\u00e9velopp\u00e9 par Arvelle Therapeutics, obtenait en effet l\u2019approbation de la Commission europ\u00e9enne pour le traitement des crises d\u2019apparition focale pharmacor\u00e9sistantes chez les adultes.<\/p>\n

Pour lire le communiqu\u00e9 de presse dans son int\u00e9gralit\u00e9, veuillez cliquer ici<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

TWYMEEG\u00ae est un m\u00e9dicament premier de sa classe dot\u00e9 d’un double m\u00e9canisme d’action unique pour le traitement du diab\u00e8te de type 2 qui s\u2019inscrit dans le paradigme actuel de traitement, en monoth\u00e9rapie ou en compl\u00e9ment d’autres traitements antidiab\u00e9tiques. L’autorisation au Japon d\u00e9clenche un paiement d’\u00e9tape de 1,75 milliard de yens japonais (environ 13,3 millions d\u2019euros,…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[78],"class_list":["post-7865","post","type-post","status-publish","format-standard","hentry","category-biodiscovery"],"acf":[],"yoast_head":"\nPoxel annonce l\u2019approbation de TWYMEEG\u00ae pour le traitement du diab\u00e8te de type 2 - ANDERA PARTNERS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Poxel annonce l\u2019approbation de TWYMEEG\u00ae pour le traitement du diab\u00e8te de type 2 - ANDERA PARTNERS\" \/>\n<meta property=\"og:description\" content=\"TWYMEEG\u00ae est un m\u00e9dicament premier de sa classe dot\u00e9 d’un double m\u00e9canisme d’action unique pour le traitement du diab\u00e8te de type 2 qui s\u2019inscrit dans le paradigme actuel de traitement, en monoth\u00e9rapie ou en compl\u00e9ment d’autres traitements antidiab\u00e9tiques. L’autorisation au Japon d\u00e9clenche un paiement d’\u00e9tape de 1,75 milliard de yens japonais (environ 13,3 millions d\u2019euros,...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/\" \/>\n<meta property=\"og:site_name\" content=\"ANDERA PARTNERS\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-23T14:23:51+00:00\" \/>\n<meta name=\"author\" content=\"Nicolas Delsert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicolas Delsert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/\"},\"author\":{\"name\":\"Nicolas Delsert\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\"},\"headline\":\"Poxel annonce l\u2019approbation de TWYMEEG\u00ae pour le traitement du diab\u00e8te de type 2\",\"datePublished\":\"2021-06-23T14:23:51+00:00\",\"dateModified\":\"2021-06-23T14:23:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/\"},\"wordCount\":285,\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"articleSection\":[\"andera Life Sciences\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/\",\"url\":\"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/\",\"name\":\"Poxel annonce l\u2019approbation de TWYMEEG\u00ae pour le traitement du diab\u00e8te de type 2 - ANDERA PARTNERS\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\"},\"datePublished\":\"2021-06-23T14:23:51+00:00\",\"dateModified\":\"2021-06-23T14:23:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.anderapartners.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Poxel annonce l\u2019approbation de TWYMEEG\u00ae pour le traitement du diab\u00e8te de type 2\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"name\":\"ANDERA PARTNERS\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\",\"name\":\"Andera Partners\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"width\":107,\"height\":44,\"caption\":\"Andera Partners\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\",\"name\":\"Nicolas Delsert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"caption\":\"Nicolas Delsert\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Poxel annonce l\u2019approbation de TWYMEEG\u00ae pour le traitement du diab\u00e8te de type 2 - ANDERA PARTNERS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/","og_locale":"fr_FR","og_type":"article","og_title":"Poxel annonce l\u2019approbation de TWYMEEG\u00ae pour le traitement du diab\u00e8te de type 2 - ANDERA PARTNERS","og_description":"TWYMEEG\u00ae est un m\u00e9dicament premier de sa classe dot\u00e9 d’un double m\u00e9canisme d’action unique pour le traitement du diab\u00e8te de type 2 qui s\u2019inscrit dans le paradigme actuel de traitement, en monoth\u00e9rapie ou en compl\u00e9ment d’autres traitements antidiab\u00e9tiques. L’autorisation au Japon d\u00e9clenche un paiement d’\u00e9tape de 1,75 milliard de yens japonais (environ 13,3 millions d\u2019euros,...","og_url":"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/","og_site_name":"ANDERA PARTNERS","article_published_time":"2021-06-23T14:23:51+00:00","author":"Nicolas Delsert","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Nicolas Delsert","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/#article","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/"},"author":{"name":"Nicolas Delsert","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c"},"headline":"Poxel annonce l\u2019approbation de TWYMEEG\u00ae pour le traitement du diab\u00e8te de type 2","datePublished":"2021-06-23T14:23:51+00:00","dateModified":"2021-06-23T14:23:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/"},"wordCount":285,"publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"articleSection":["andera Life Sciences"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/","url":"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/","name":"Poxel annonce l\u2019approbation de TWYMEEG\u00ae pour le traitement du diab\u00e8te de type 2 - ANDERA PARTNERS","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/#website"},"datePublished":"2021-06-23T14:23:51+00:00","dateModified":"2021-06-23T14:23:51+00:00","breadcrumb":{"@id":"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.anderapartners.com\/en\/poxel-announces-the-approval-of-twymeeg\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.anderapartners.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Poxel annonce l\u2019approbation de TWYMEEG\u00ae pour le traitement du diab\u00e8te de type 2"}]},{"@type":"WebSite","@id":"https:\/\/www.anderapartners.com\/fr\/#website","url":"https:\/\/www.anderapartners.com\/fr\/","name":"ANDERA PARTNERS","description":"","publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.anderapartners.com\/fr\/#organization","name":"Andera Partners","url":"https:\/\/www.anderapartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","width":107,"height":44,"caption":"Andera Partners"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c","name":"Nicolas Delsert","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","caption":"Nicolas Delsert"}}]}},"_links":{"self":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/7865","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/comments?post=7865"}],"version-history":[{"count":0,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/7865\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/media?parent=7865"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/categories?post=7865"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}